Allspring Global Investments
ESPR

Allspring Global Investments’s Esperion Therapeutics ESPR Stock Holding History

Allspring Global Investments’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-770
Closed -$1.27K – 1976
2024
Q3 		$1.27K Buy
+770
New +$1.55K ﹤0.01% 2311
2023
Q3 		– Sell
-42,802
Closed -$59.5K – 2815
2023
Q2 		$59.5K Sell
42,802
-162,900
-79% -$227K ﹤0.01% 2245
2023
Q1 		$327K Buy
205,702
+205,296
+50,566% +$1.06M ﹤0.01% 1692
2022
Q4 		$2.53K Buy
+406
New +$2.9K ﹤0.01% 2840

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Allspring Global Investments's ESPR Position: Q4 2024 in Review

Allspring Global Investments sold out of Esperion Therapeutics (ESPR) in Q4 2024, closing a stake of 770 shares — an estimated $1.27K sold.

Allspring Global Investments first reported a position in ESPR in Q4 2022 and held it in 4 quarters. The position peaked at $327K in Q1 2023. 189 funds tracked by Wall St. Rank hold ESPR as of Q4 2024.

  • Allspring Global Investments reported no remaining Esperion Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 770 Esperion Therapeutics shares in Q4 2024, an estimated $1.27K.
  • Allspring Global Investments first reported a position in Esperion Therapeutics in Q4 2022 and held it in 4 quarters.
  • Allspring Global Investments's Esperion Therapeutics position peaked at $327K in Q1 2023.
  • 189 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.